DOI QR코드

DOI QR Code

Bioequivalence of GomcillinTM Capsule to FamoxinTM Capsule (Amoxicillin 500 mg)

파목신 캅셀(아목시실린 500 mg)에 대한 곰실린 캅셀의 생물학적동등성

  • Lee, Yun-Young (Department of Drug Development Service, BioCore Co., Ltd.) ;
  • Choi, Mee-Hee (Department of Drug Development Service, BioCore Co., Ltd.) ;
  • Lee, Kyung-Ryul (Department of Pharmacokinetics, Seoul Medical Science Institute, Seoul Clinical Laboratories, Department of Drug Development Service, BioCore Co., Ltd.) ;
  • Lee, Hee-Joo (Department of Pharmacokinetics, Seoul Medical Science Institute, Seoul Clinical Laboratories, Department of Drug Development Service, BioCore Co., Ltd.)
  • 이윤영 (바이오코아주식회사) ;
  • 최미희 (바이오코아주식회사) ;
  • 이경률 (서울의과학연구소, 바이오코아주식회사) ;
  • 이희주 (서울의과학연구소, 바이오코아주식회사)
  • Published : 2004.08.20

Abstract

A bioequivalence study of $Gomcillin^{TM}$ capsules (DAEWOONG Pharmaceutical Co., Korea) to $Famoxin^{TM}$ capsules (Dong Wha Pharm. Ind. Co., Korea) was conducted according to the guideline of Korea Food and Drug Administration (KFDA). Twenty four healthy male Korean volunteers received each medicine at the amoxicillin dose of 500 mg in a $2{\times}2$ crossover study. There was a one-week wash out period between the doses. Plasma concentrations of amoxicillin were monitored by a high-performance liquid chromatography for over a period of 8 hours after the administration. $AUC_t$ (the area under the plasma concentration-time curve from time zero to 8 hr) was calculated by the linear trapezoidal rule method. $C_{max}$ (maximum plasma drug concentration) and $T_{max}$ (time to reach $C_{max}$) were compiled from the plasma concentration-time data. Analysis of variance was carried out using logarithmically transformed $AUC_t$ and $C_{max}$. No significant sequence effect was found for all of the bioavailability parameters indicating that the crossover design was properly performed. The 90% confidence intervals of the $AUC_t$ ratio and the $C_{max}$ ratio for $Gomcillin^{TM}/Famoxin^{TM}$ were $log0.91\;{\sim}\;log1.03$ and $;log0.93\;{\sim}\;log1.10$, respectively. These values were within the acceptable bioequivalence intervals of $log0.80\;{\sim}\;log1.25$. Thus, our study demonstrated the bioequivalence of $Gomcillin^{TM}$ and $Famoxin^{TM}$ with respect to the rate and extent of absorption.

Keywords

References

  1. M. Kidwai, P. Sapra and K.R Bhushan, Synthetic strategies and medical properties of beta-lactams. Curr Med. Chern., 6, 195-215 (1999)
  2. American Society of Health-System Pharmacists, Amoxi-cillin. AHFS Drug Information, 380-382 (2001)
  3. L.R. Pires de Abreu, RM. Ortiz, S.C. de Castro and J.Jr. Pedrazzoli, HPLC determination of amoxicillin comparative bioavailability in healthy volunteers after a single dose administration. J. Pharm. Pharm. Sci., 6, 223-230 (2003)
  4. D. Zarowny, R Ogilvie, D. Tamblyn, C. MacLeod and J.Ruedy, Pharmacokinetics of amoxicillin. Clin. Pharmacol. Ther., 16, 1045-1051 (1974) https://doi.org/10.1002/cpt19741661045
  5. G.A. Digenis, E.P. Sandefer, R.C. Page, W.J. Doll, T.B. Gold and N.B. Darwazeh, Bioequivalence study of stressed and nonstressed hard gelatin capsules using amoxicillin as a drug marker and gamma scintigraphy to confirm time and GI location of in vivo capsule rupture. Pharm. Res., 17, 572-582 (2000) https://doi.org/10.1023/A:1007568900147
  6. 식품의약품안전청 고시 제 2002-60호, 생물학적동등성시험기준 (2002. 11. 22)
  7. Y.J. Lee, Y.G. Kim, M.G. Lee, S.J. Chung, M.H. Lee and C.K. Shim, Analysis of bioequivalence study using log-transformed model. Yakhakhoeji, 44, 308-314 (2000)
  8. 식품의약품안전청 고시 재 2002-61호, 의약품동등성시험관리규정 (2002. 11. 22)